On May 4, 2023 Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, reported its participation in the 26th American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, May 16-20, in Los Angeles (Press release, Ginkgo Bioworks, MAY 4, 2023, View Source;cell-therapy-asgct-annual-meeting-301815435.html [SID1234631071]). Ginkgo will present data on its high-throughput screening platform for chimeric antigen receptor (CAR) libraries, which can enable discovery of CAR variants with desired characteristics. This capability has the potential to discover CAR-T therapeutic candidates that are effective against solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ginkgo recently announced the launch of Ginkgo Cell Therapy Services at its annual Ferment conference. These services empower customers with massively parallel testing of genetic designs, allowing them to leverage vast biological diversity to improve their products. Ginkgo’s ultra high throughput mammalian cell engineering foundry is well suited to address many outstanding problems in cell therapy, including CAR-T. Ginkgo is actively developing high throughput platforms to enhance CAR efficacy and safety by exploring novel construct designs and incorporating synthetic regulatory elements like inducible promoters. In addition to CAR optimization, Cell Therapy Services include immune cell armoring, synthetic promoters, immune cloaking and novel gene editing tools. You can learn more at Ginkgo’s Cell Therapy Services Virtual Event on May 31. Register here.
"All six of the approved CAR-T therapies on the market use one of two signaling domains, which were identified 20 years ago. Since then, the ability to read and write DNA has improved dramatically. Ginkgo is harnessing its ability to generate massive libraries of unique CAR designs with different signaling domains, which can then be screened in an assay that mimics a solid tumor environment," said Shawdee Eshghi, Senior Director, Mammalian Engineering, Ginkgo Bioworks. "In head-to-head tests of these designs, Ginkgo is identifying a number of designs that show improved performance compared to designs with standard signaling domains. We’re excited to present this data to the ASGCT (Free ASGCT Whitepaper) community, especially as this flexible platform is available to partners and can also be used for other applications like natural killer cells."
Info on the poster presentation is listed below, and the full abstract is available on the ASGCT (Free ASGCT Whitepaper) meeting website.
High-Throughput Pooled Screen of CAR Library Identifies Essential Signaling Features of CAR-T Cells That Resist Immunosuppression
Abstract number: 858
Session: Thursday Poster Session
Date and Time: Thursday, May 18, 2023 12:00 PM PT